Urologix Names Interim CEO
Posted on December 10, 2012 @ 12:38 pm
Minneapolis, Minn.-based Urologix Inc.’s CEO Stryker Warren resigned at the end of November. Replacing him as interim CEO is Gregory Fluet, who has served as the company’s chief operating officer and executive vice president since 2008.
“Stryker has provided the right leadership at a critical time in Urologix’s history,” said Urologix’s Chairman Mitchell Dann. “His urology relationships and commitments to patients and employees helped transform the company.”
Fluet is a 1991 graduate of Stanford University, where he studied mechanical engineering. He has been a board observer of Hansen Medical, a robotics company, and a project manager at Freeman, Sullivan & Co., an energy consulting firm. He has experience assisting portfolio companies with intellectual property, financial analysis, market research, and clinical research. Fluet joined Sapient Capital Management in the spring of 2002 and worked as an analyst and an associate until 2008, when he joined Urologix. He is also currently a consultant at Sapient Capital Management LLC.
“Greg has been a key member of the executive team during Stryker’s tenure and the board is confident he can lead the company during this transition period,” added Dann. “The board has begun the process of looking for a permanent CEO.”
Urologix develops minimally invasive medical products for the treatment of obstruction and symptoms due to BPH.
Please visit our sister sites:
The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.